Shareholders in Valeant Pharmaceuticals (TSX:VRX) used the company’s annual general meeting Tuesday as a forum to vent their gripes with the struggling drugmaker.
Some stockholders told CEO Joseph Papa that they were unhappy with Valeant’s low share price, insufficient response to negative media coverage and his predecessor’s lawsuit against the company seeking extra compensation.
Their frustration came after Papa said Valeant is making progress to stabilize itself after nearly two years of challenges, including a stock price that has plummeted from nearly $350 on the Toronto Stock Exchange in August 2015 to about $14 early Tuesday morning.
(Sponsored)
For the fifth year in a row, Ottawa will become the epicentre of Canadian culinary excellence in late January. Chefs from Ottawa, Vancouver, Edmonton, Calgary, Saskatoon, Winnipeg, Toronto, Montreal, Moncton
New dean of uOttawa’s Faculty of Engineering brings a history of entrepreneurship and innovation
Caroline Cao has been impressed by many aspects of uOttawa’s Faculty of Engineering since being appointed dean in August. But it was after the faculty’s recent Design Day – a
Papa also said Valeant has made inroads to reduce its debt, adding that he doesn’t believe its current share price reflects the efforts it has made to turn itself around.
Still, he said a proposal to change the company’s name given the negative perception tarnishing it remains under consideration.
